Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth $11. ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth ...

Last week, the European Commission approved Novo Holdings' acquisition of Catalent and Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings. The deal for the three ...

The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations on Wednesday. Here’s what you need to know.

the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, on Wednesday sealed its $16.5 billion deal for Catalent (CTLT.N), opens new tab, as the Danish drugmaker looks to boost ...

Novo Nordisk to invest $1.2 billion in Denmark for a new production site, creating 400 permanent jobs by 2027. Novo Holdings completes Catalent acquisition despite opposition, impacting Novo ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

The Danish investment company Novo Nordisk A/S has received approval from the US Federal Trade Commission (FTC) to acquire the production assets of Catalent Inc., one of the world's largest ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...